登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>CD27 Ligand >CDL-H52Da

Human CD27 Ligand / CD70 Protein, His,Flag Tag, active trimer (MALS verified)

分子别名(Synonym)

CD70,CD27LG,TNFSF7,TNFSF7G,CD27L

表达区间及表达系统(Source)

Human CD27 Ligand Protein, His,Flag Tag (CDL-H52Da) is expressed from human 293 cells (HEK293). It contains AA Ser 52 - Pro 193 (Accession # P32970-1 ) trimer Design.

Predicted N-terminus: His

蛋白结构(Molecular Characterization)

This protein carries a polyhistidine tag at the N-terminus, followed by a flag tag.

The protein has a calculated MW of 49.3 kDa. The protein migrates as 50-60 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.

内毒素(Endotoxin)

Less than 1.0 EU per μg by the LAL method.

纯度(Purity)

>95% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.
 

电泳(SDS-PAGE)

CD27 Ligand SDS-PAGE

Human CD27 Ligand Protein, His,Flag Tag on SDS-PAGE under non-reducing (NR) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).

SEC-MALS

CD27 Ligand SEC-MALS

The purity of Human CD27 Ligand Protein, His,Flag Tag (Cat. No. CDL-H52Da) is more than 90% and the molecular weight of this protein is around 55-70 kDa verified by SEC-MALS.

Report

 

活性(Bioactivity)-ELISA

CD27 Ligand ELISA

Immobilized Human CD27 Ligand Protein, His,Flag Tag (Cat. No. CDL-H52Da) at 2 μg/mL (100 μL/well) can bind Human CD27, Fc Tag (Cat. No. CD7-H5254) with a linear range of 2-125 ng/mL (QC tested).

Protocol

CD27 Ligand ELISA

Serial dilutions of Anti-CD27 Ligand (cusatuzumab) Antibody, Human IgG1 were added into Human CD27 Ligand Protein, His,Flag Tag (Cat. No. CDL-H52Da) : Biotinylated Human CD27, Fc,Avitag (Cat. No. TN7-H82F6) binding reactions. The half maximal inhibitory concentration (IC50) is 0.42856 μg/mL (Routinely tested).

Protocol

CD27 Ligand ELISA

Immobilized Human CD27, Fc Tag (Cat. No. CD7-H5254) at 5 μg/mL (100 μL/well) can bind Human CD27 Ligand Protein, His,Flag Tag (Cat. No. CDL-H52Da) with a linear range of 0.6-20 ng/mL (Routinely tested).

Protocol

 

背景(Background)

Cluster of Differentiation 70 (CD70) is also known as CD27 ligand (CD27L / CD27LG), TNFSF7, TNFSF7G, is a type II transmembrane glycoprotein belonging to the TNF superfamily (TNFSF) and is a surface antigen found on activated T-and B-lymphocytes and mature dendritic cells. Binding of CD70 to its receptor CD27 induces in priming, effector functions, differentiation and memory formation of T-cells, and thus is invloved in the biological processes including T-cell activation, the proliferation of costimulated T-cells, as well as the generation of cytolytic T-cells. CD70 on T cells provides costimulatory signals that are required for T cell proliferation, clonal expansion and the promotion of effector T cell formation. CD70 on mouse B cell has been shown to inhibit terminal differentiation of activated B cells into plasma cells and enhances commitment to memory B cell responses. CD70 induces proliferation and IFNγ production, on NK cells.

文献引用(Citations)

 

前沿进展

 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
CD27 Ligand靶点信息
英文全称:CD70 antigen
中文全称:CD70抗原
种类:Homo sapiens
上市药物数量:0详情
临床药物数量:17详情
最高研发阶段:临床二期
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定